1. Scrip
  2. >>New Products

SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors

Nirogacestat Also In Anti-BCMA Combo, Ovarian Cancer Studies

 
• By Mandy Jackson

SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply. 

FDA approved written on translucent black space
SpringWorks will file for approval in Europe next year • Source: Shutterstock

SpringWorks Therapeutics Inc. will soon launch its first product after the US Food and Drug Administration approved the small molecule gamma secretase inhibitor Ogsiveo (nirogacestat) for adults with progressing desmoid tumors who require systemic treatment. As the first-ever drug approved to treat the rare tumors, Ogsiveo appears poised to enjoy a warm welcome from doctors and patients who have been searching for alternatives to often ineffective surgeries and off-label medicines.

Key Takeaways

  • The US FDA approved Ogsiveo on 27 November to treat adults with progressing desmoid tumors who require systemic treatment. The drug will be available within five to 10 days.

Stamford, CT-based SpringWorks, which plans to make the drug available in the US within five to 10 days of its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Two Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Pipeline Watch: Four Approvals And Four Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer Sees Opportunities For Jascayd In Evolving China IPF Landscape

 
• By Xu Hu

Boehringer’s PDE4B inhibitor Jascayd was approved for IPF in China on Oct. 22, marking its second nod globally soon after the US. The German firm discusses with Scrip the opportunities and challenges in this market.

More from Scrip

Bayer Boss Cautious On Late-Stage Deals Despite Beyonttra Success

 
• By Kevin Grogan

CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”

Investors Shower Chinese In Vivo CAR-T Biotechs With Quick Cash

 
• By Dexter Jie Yan

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas

Sagimet may shift focus to later-stage MASH while it lines up Phase III financing. Altimmune expects its dual agonist to show efficacy and tolerability, while GSK is readying efimosfermin as the third FGF21 analog into Phase III for MASH.